These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 422947)

  • 1. A critical appraisal of a further three new commercial digoxin radioimmunoassay kits with reference to cross-reacting substances.
    Wood WG; Wachter C
    J Clin Chem Clin Biochem; 1979 Feb; 17(2):77-83. PubMed ID: 422947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A simplified radioimmunoassay for digoxin determination using a 125-j-labelled, solid-phase kit (author's transl)].
    Doering W; Blümel E
    Klin Wochenschr; 1978 May; 56(10):497-502. PubMed ID: 651281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of spironolactone and its metabolite canrenone on serum digoxin assays.
    Foukaridis GN
    Ther Drug Monit; 1990 Jan; 12(1):82-4. PubMed ID: 2305425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors of importance for valid digitalis assays particularly for the determination of digoxin in plasma and urine.
    Molin L
    Acta Pharmacol Toxicol (Copenh); 1986; 59 Suppl 4():1-62. PubMed ID: 3739734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Digoxin assays: frequent, substantial, and potentially dangerous interference by spironolactone, canrenone, and other steroids.
    Steimer W; Müller C; Eber B
    Clin Chem; 2002 Mar; 48(3):507-16. PubMed ID: 11861441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spironolactone-associated digoxin radioimmunoassay interference.
    Silber B; Sheiner LB; Powers JL; Winter ME; Sadée W
    Clin Chem; 1979 Jan; 25(1):48-50. PubMed ID: 761378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reassessment of cross-reactivity of spironolactone metabolites with four digoxin immunoassays.
    Pleasants RA; Williams DM; Porter RS; Gadsden RH
    Ther Drug Monit; 1989; 11(2):200-4. PubMed ID: 2655203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of spironolactone, potassium canrenoate, and their common metabolite canrenone on Dimension Vista Digoxin Assay.
    Dasgupta A; Johnson MJ
    J Clin Lab Anal; 2010; 24(6):413-7. PubMed ID: 21089173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferences and recovery of digitalis glycoside preparations using commercial radioimmunoassay kits for digoxin and digitoxin.
    Kinsun H; Moulin MA
    J Med; 1977; 8(6):425-34. PubMed ID: 272436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Precision of digoxin radioimmunoassays and matrix effects: four kits compared.
    Bergdähl B; Molin L
    Clin Biochem; 1981 Apr; 14(2):67-71. PubMed ID: 7296815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay.
    Dasgupta A; Tso G; Wells A
    Ther Drug Monit; 2008 Dec; 30(6):744-7. PubMed ID: 18824952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of assay conditions on cross reactivity of digoxin-like immunoreactive substance(s) with radioimmunoassay kits.
    Pudek MR; Seccombe DW; Jacobson BE; Humphries K
    Clin Chem; 1985 Nov; 31(11):1806-10. PubMed ID: 4053349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new turbidometric digoxin immunoassay on the ADVIA 1650 analyzer is free from interference by spironolactone, potassium canrenoate, and their common metabolite canrenone.
    Datta P; Dasgupta A
    Ther Drug Monit; 2003 Aug; 25(4):478-82. PubMed ID: 12883233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross reactivity of digitoxin and spironolactone in two radioimmunoassays for serum digoxin.
    Müller H; Bräuer H; Resch B
    Clin Chem; 1978 Apr; 24(4):706-9. PubMed ID: 639280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, potassium canrenoate, and their common metabolite canrenone.
    DeFrance A; Armbruster D; Petty D; Cooper KC; Dasgupta A
    Ther Drug Monit; 2011 Feb; 33(1):128-31. PubMed ID: 21079546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variable cross-reactivity of digoxin metabolites in digoxin immunoassays.
    Valdes R; Brown BA; Graves SW
    Am J Clin Pathol; 1984 Aug; 82(2):210-3. PubMed ID: 6380268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new enzyme-linked chemiluminescent immunosorbent digoxin assay is virtually free from interference of spironolactone, potassium canrenoate, and their common metabolite canrenone.
    Dasgupta A; Kang E; Datta P
    J Clin Lab Anal; 2006; 20(5):204-8. PubMed ID: 16960898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Negligible interference by spironolactone and prednisone in digoxin radioimmunoassay.
    Ravel R
    Clin Chem; 1975 Nov; 21(12):1801-3. PubMed ID: 1183001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Four kits for plasma digoxin radioimmunoassay compared.
    Bergdahl B; Molin L; Lindwall L; Dahlström G; Scherling IL; Bertler A
    Clin Chem; 1979 Feb; 25(2):305-8. PubMed ID: 759025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variability among commercially available digoxin radioimmunoassay kits in cross reactivity to dihydrodigoxin.
    Kramer WG; Kinnear NL; Morgan HK
    Clin Chem; 1978 Jan; 24(1):155-7. PubMed ID: 618648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.